Literature DB >> 9694927

Blockade of HERG and Kv1.5 by ketoconazole.

R Dumaine1, M L Roy, A M Brown.   

Abstract

Ketoconazole, a widely used fungicide in patients, has been associated with Q-T prolongation and torsade de pointes when co-administered with terfenadine (Seldane). Both compounds use the same cytochrome-P450 metabolic pathway, resulting in an increase in plasma concentration of terfenadine. We previously showed that terfenadine blocked HERG (Human Ether-a-Gogo Related Gene), an important component of the repolarizing cardiac delayed rectifier IK with concentration needed to obtain 50% of the block (IC50) in the therapeutic range (300 nM). Another target is Kv1.5 (delayed outward rectifier potassium current), an important component of human atrial ultrarapid delayed rectifier current. Whether Kv1.5 and HERG proteins are direct targets for ketoconazole has yet to be addressed. We heterologously expressed HERG and Kv1.5 in Xenopus oocytes and compared their sensitivities to ketoconazole. HERG and Kv1.5 currents were reduced comparably with apparent IC50 values of 49 microM and 107 microM, respectively, when measured using the two-microelectrode recording technique. The differences in the IC50 may help explain the preferential ventricular origin of the ketoconazole-associated arrhythmias during overdose. The mechanism of block was different between Kv1.5 and HERG. Cumulative application of terfenadine and ketoconazole at their respective IC50 concentrations resulted in current reductions that suggest an additive rather than a competitive type of block by the two drugs. We conclude that ketoconazole may potentiate the effects of terfenadine first by an indirect pharmacokinetic action to elevate plasma levels and second by a direct pharmacodynamic action on HERG currents. These potential dual actions on HERG currents suggest that precautions should be taken in long-term ketoconazole treatment, particularly for patients who have decreased liver function or are on a drug regimen requiring simultaneous medications that use cytochrome-P450 for breakdown, such as terfenadine or erythromycin, or Class III antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694927

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome?

Authors:  R Dumaine; C Antzelevitch
Journal:  J Mol Cell Cardiol       Date:  2006-07-25       Impact factor: 5.000

Review 2.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Transfer of rolf S3-S4 linker to HERG eliminates activation gating but spares inactivation.

Authors:  Frank S Choveau; Aziza El Harchi; Nicolas Rodriguez; Bénédicte Louérat-Oriou; Isabelle Baró; Sophie Demolombe; Flavien Charpentier; Gildas Loussouarn
Journal:  Biophys J       Date:  2009-09-02       Impact factor: 4.033

Review 4.  Short QT syndrome.

Authors:  Ramon Brugada; Kui Hong; Jonathan M Cordeiro; Robert Dumaine
Journal:  CMAJ       Date:  2005-11-22       Impact factor: 8.262

5.  Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents.

Authors:  Miao Tian; Ming-Qing Dong; Shui-Wha Chiu; Chu-Pak Lau; Gui-Rong Li
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Voriconazole-induced bradycardia without QT interval prolongation: a possible non-concentration-dependent adverse effect.

Authors:  Sébastien Perbet; Raiko Blondonnet; Renaud Guérin; Sophie Cayot-Constantin; Jean-Michel Constantin
Journal:  Intensive Care Med       Date:  2013-01-05       Impact factor: 17.440

7.  Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole.

Authors:  Borje Darpo; Georg Ferber; Meijian Zhou; Mark Sumeray; Philip Sager
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09-30       Impact factor: 1.468

8.  Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.

Authors:  Christopher Banfield; Jerry Herron; Anther Keung; Desmond Padhi; Melton Affrime
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

10.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Authors:  James T Milnes; Olivia Crociani; Annarosa Arcangeli; Jules C Hancox; Harry J Witchel
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.